DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim of Foreign Priority
Foreign priority has not been claimed.
Status of the Claims
Claims 1-12, 14 and 15 are pending and examined.
Drawings
Color photographs and color drawings are not accepted in utility applications unless a petition filed under 37 CFR 1.84(a)(2) is granted. Any such petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification:
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2).
Claim Objections
Applicant is advised that should claim 1 be found allowable, claims 2-10 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). It is not presently clear, but if a determination is made that all claims are only drawn to a single form in the Specification referred to as “Type 8,” each claim will be considered directed to an identical product.
Claim Rejections - 35 USC § 112
Claims 1-12 and 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
With regard to claims 1-12, claim 1 claims peaks for Type 8 at 10.5 and 24.7. However, Type 8 in the Specification does not show a peak at 10.5 or 24.7. While a peak is shown at 10.3 in Table 1, a peak is not shown within the margin of error at 24.7 (i.e., 24.5-24.9).
With regard to claim 6, the phrase “substantially the same” means. The phrase is defined to mean that at least 50% of its features appear in the Figure. However, this does not clarify what the remaining 50% of the figure must look like if an XRPD is produced for a specific polymorph. It is not clear how only 50% of an XRPD can match a polymorph produced in a specific manner as described in the Specification.
With regard to claims 11 and 12, a crystalline form will often change when it is incorporated into a pharmaceutical composition. It is not clear if the crystalline form claimed once combined with a diluent, excipient or carrier of any type will remain crystalline form Type 8.
With regard to claim 15, the term “obtainable” merely means that the form can be obtained through a specific process. This is not a requirement of the claim as the form can also be obtained in other ways. However, claim 15 must further limit claim 14 and so the steps described in claim 15 must further limit claim 14. Therefore, using the term is “obtained” by the process described in claim 14 would be proper and clarifying.
Claim Rejections - 35 USC § 112
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 3 and 5 recite the broad recitation comprising at least one or at least two peaks, and the claim also recites at least two, three or four specific peaks (claim 3) and at least two, five, ten, fifteen further peaks (claim 5), respectively. These claims require only one or two and then allow for many more peaks, which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 14 and 15 are rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling. The disclosure does not enable one of ordinary skill in the art to practice the invention without identifying the steps that provide for producing the claimed product through a process that yields a solid that is easy to filter and dry, and one that is a soluble intermediate for the synthesis of the lysine salt. See par. 146. These are critical or essential to the practice of the invention but not included in the claim(s). See In re Mayhew, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976). In particular, claim 14 includes providing any solution of API, adding any second solvent, and stirring. There are no specific components, no percentages or concentrations, temperatures, durations, or any other metrics required. Steps “d” and “e” are each optional.
However, the Specification is limited to the following specific steps for preparation Type 8.
PNG
media_image1.png
138
658
media_image1.png
Greyscale
Thus, specific volumes of DMSO were added, followed by the anti-solvent THF dropwise to gradually precipitate while the suspension was stirred for 24 hours at room temperature. The isolation and drying steps were performed with centrifugation and drying was performed at 50°C. Most of these steps are not claimed nor required.
Thus, it is far from clear that the above description is properly and sufficiently captured by the providing a solution in a first solvent system, adding a second solvent system and stirring the mixture for at least 1 hour.
As such claim 14 is rejected as not providing sufficient specificity in the claims to enable a POSA yield the claimed product. The product that is formed must yield a specific XRPD and DSC, as well as purity with low levels of residual solvent, as claimed.
To overcome this rejection Applicant can add specific steps and components to claim 14 that are required to produce a claimed product. The language set forth in paragraph 156, above, should be considered for incorporation into the claims.
The examiner notes that [A] claim which omits matter disclosed to be essential to the invention, as described in the specification or in other statements of record, may also be rejected under 35 U.S.C. § 112(a) as not enabling. {See In re Mayhew, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976); and MPEP § 2164.08(c)}.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-6, 9-11, 12 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Bachav et al., (US2020/0289485).
Bachav teaches the compound pritelivir for treating and preventing herpes simplex virus infections. See par. 1. Bachav teaches crystalline forms with diffraction patterns shown in Figures 7-11, 26, 27, 32, 33, 37, 38, 43, 44, e.g.
Figure 10, e.g., lists peaks at 10.7 and 24.8. The claimed range in claim 1 includes 10.3-10.7 and 24.5-24.9. Thus, the peaks described in Figure 10 include those at both 10.5 and 24.7 within the claimed margin of error.
Further, Figure 10 also indicates peaks at the following positions: 17.5, 18.1, 22.8, and 23.2. These four peaks fall within the margin of error for claimed peaks at 17.4 (17.2-17.6), 17.9 (17.7-18.1), 23.0 (22.8-23.2), and 23.2 (23.0-23.4).
The form described in Figures 10 and 11, e.g., are pure crystalline solid. See par. 492. Further, the form can be in the form of a composition with excipients, e.g. See prior art claim 6. The process described in preparing can include suspending the API in ethanol and water and benzene sulfonic acid is added as solution in water. The solution is stirred during 90 minutes. See par. 239. Multiple different processes describe mixing solutions and adding additional solution under stirring for periods of time to include over 1 hour. See par.’s 347, 365.
With regard to claim 6, the prior art shows the following peaks which fall within +/- 0.2 of those described in Table 1. Those peaks are: 10.1, 16.2, 17.5, 18.1, 20.9, 21.3, 22, 22.8, 23.2, 23.7, 23.9, 25, 25.2, 25.7, 26.1, 27.5, 28.2, 28.8, 29.5, 29.8, and others. The number of peaks that overlap falls within the definition provided in the Specification of “substantially” similar.
With regard to claim 10, the processes described by the prior art including filtering, drying, a description of purity would lead a POSA to understand that the amount of residual solvent is minimized.
Claim Rejections - 35 USC § 102/103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-12 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by, or in the alternative, obvious over 35 U.S.C. 103, Bachav et al., (WO2018/096170) (cited in ISR).
Bachav teaches the compound pritelivir for treating and preventing herpes simplex virus infections. See p1. Figure 5 describes the DSC of a form. The DSC form shown includes one that appears substantially similar to that shown and claimed in the instant claims. The range of peak in the prior art appears to be from approximately 220 to 245 °C.
Peaks shown in Table 7 includes those at 10.1, 13.6, 14.0, 15.5, 17.4, 17.9, 18.7, 20.9, 21.6, 22.1, 23.3, and 24, among others. These peaks fall within the margin of error claimed.
The pharmaceutical compositions are described as having a very high degree of purity. See p1. Excipients and other agents are taught for use with the API. See p12.
The reduction and minimization of residual solvents is taught to be low to avoid inclusion of water and solvent and is preferred as reduced. See p35. A POSA would immediately envisage this to be below 2%, e.g.
In one method of preparing, a solution is obtained with the API is added and a solution is formed in steps c. Then water is added to a solution formed in step g. Stirring and drying steps are then undertaken. Stirring can occur for over 1 hour. See p21, steps d, e.g. The examiner notes that DMSO is taught as a solvent.
A POSA would immediately envisage and or arrive at the instantly claimed product in view of the cited prior art prior to the filing of the instant application. One would be motivated to do so because a crystalline form with numerous overlapping and/or identical XRPD peaks are taught by the prior art with a similar and substantially overlapping DSC. Further, the use of solvents as well as generic precipitation, purification, and isolation techniques are known to employ solvents including DMSO. See p29. Further, limiting residual solvent and increasing stability and purity are well-described motivations. As such, there is a reasonable and predictable expectation at arriving at the claimed product and methods in view of the cited prior art.
As such, no claim is allowed.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JARED D BARSKY whose telephone number is (571)272-2795. The examiner can normally be reached on 9-5 M-F.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JARED BARSKY/Primary Examiner, Art Unit 1628